Forxiga

DRUG11 trials

Sponsors

AstraZeneca AB, AstraZeneca, Population Health Research Institute, AstraZeneca Turkey, EMS

Conditions

Autonomic Neuropathy, DiabeticChronic HF and comorbid impairment of kidney function who had a recent HF event to evaluate the effect of balcinrenone/dapagliflozin versus dapagliflozin alone on HF events and cardiovascular (CV) deathChronic Kidney Disease and AlbuminuriaDiabetes MellitusGlomerulonephritisHealthyHypoxiaMitochondrial Alteration

Phase 1

Pharmacokinetics and Safety/Tolerability Profiles of DA-2811 in Healthy Subjects

CompletedNCT04473417

Dong-A ST Co., Ltd.Healthy

Start: 2020-08-04End: 2020-10-12Updated: 2021-03-05

Phase 2

A Phase IIb, Multicentre, Randomised, Double-Blind, Dose-finding Study to Evaluate the Efficacy, Safety and Tolerability of Balcinrenone in Combination with Dapagliflozin Compared with Dapagliflozin in Patients with Chronic Kidney Disease and Albuminuria

CompletedCTIS2023-509709-63-00

AstraZeneca ABChronic Kidney Disease and Albuminuria

Start: 2024-07-30End: 2025-05-09Target: 85Updated: 2025-04-23

Impact of Dapagliflozin for the Regulation of Immunological Activity in Membranous Nephropathy

Not yet recruitingNCT07096986

Centre Hospitalier Universitaire de NiceGlomerulonephritis

Start: 2025-11-01End: 2027-11-30Target: 20Updated: 2025-07-31

Evaluating Safe Ketone Thresholds To Minimise Ketosis in People With Type 1 Diabetes Using Dapagliflozin

Not yet recruitingNCT07225465

St Vincent's Hospital MelbourneType 1 Diabetes Mellitus

Start: 2026-02-28End: 2028-02-29Target: 115Updated: 2025-11-06

Phase 3

Efficacy and Safety of Lima Association in the Control of Type II Diabetes Mellitus.

WithdrawnNCT03766750

EMSType2 Diabetes Mellitus

Start: 2021-12-31End: 2023-11-30Updated: 2022-07-27

A Phase III, Randomised, Double-blind Study to Evaluate the Effect of Balcinrenone/Dapagliflozin, Compared with Dapagliflozin, on the Risk of Heart Failure Events and Cardiovascular Death in Patients with Heart Failure and Impaired Kidney Function

RecruitingCTIS2023-508162-15-00

AstraZeneca ABChronic HF and comorbid impairment of kidney function who had a recent HF event to evaluate the effect of balcinrenone/dapagliflozin versus dapagliflozin alone on HF events and cardiovascular (CV) death

Start: 2024-07-12Target: 1194Updated: 2026-01-20

Phase 4

Remission Evaluation of a Metabolic Intervention in Type 2 Diabetes With Forxiga

CompletedNCT02561130

Population Health Research InstituteType 2 Diabetes Mellitus

Start: 2015-12-31End: 2018-12-31Updated: 2020-11-24

Acute Effects of SGLT2 Inhibition on Renal Oxygenation and Autonomic Function in Type 1 Diabetes

CompletedNCT04193566

Steno Diabetes Center CopenhagenAutonomic Neuropathy, Diabetic, Hypoxia, Mitochondrial Alteration +2

Start: 2020-02-01End: 2021-01-01Updated: 2021-02-03

Clinical Trial to Evaluate the Efficacy and Safety of DA-2811 When Added to Ongoing Metformin Monotherapy in Patients with Type 2 Diabetes Who Have Inadequate Glycemic Control

CompletedNCT05743907

Dong-A ST Co., Ltd.Diabetes Mellitus

Start: 2023-04-25End: 2025-03-10Updated: 2025-03-14

Unknown Phase

forREAL: FORXIGA PRESCRIPTION EVENT MONITORING PROGRAM (PEMP)

TerminatedNCT01944618

AstraZenecaType 2 Diabetes

Start: 2013-10-31End: 2015-10-31Target: 5000Updated: 2016-09-13

Dapagliflozin in Type 2 Diabetes Patients, a Retrospective Cohort Study From Turkey

CompletedNCT03407196

AstraZeneca TurkeyType 2 Diabetes Mellitus

Start: 2017-05-24End: 2018-02-28Updated: 2018-03-07

Related Papers

Acute effects of dapagliflozin on renal oxygenation and perfusion in type 1 diabetes with albuminuria: A randomised, double-blind, placebo-controlled crossover trial.

2021-06-2852 citations